We apply an entrepreneurial spirit to everything we do. We build long lasting relationships with our clients based on mutual trust. Vator Securities executes on opportunities that accelerate growth for its client companies whilst delivering results to the firm’s sophisticated investor clientele.
Vator Securities is led by experienced professionals who have between 15 to 25 years of capital market and advisory experience from some of the world’s most prominent investment banks. Our service offering includes:
- Pre-IPO Financing
- IPOs and Secondaries
- Capital Markets Advisory
- Strategic Advisory
- Equity Research
Vator Securities distinguishes itself by the firm’s ability to raise capital from traditional institutional investors, as well as from its proprietary global network of family offices and high net worth investors. The unique network of investors implies that Vator Securities can source capital irrespective of financial market sentiments and create liquidity in the stock post IPO.
At Vator Securities every project is more than a single transaction. We specialize in providing partnerships where we work long-term with the client and support the value creation of a company long before a transaction commences. We focus on building a long-term strategy for our clients by guiding and consulting extensively throughout the entire life cycle – from idea to completion, but also through follow-ups and post transaction consulting and support.
Respiratorius
SEK 25m | Directed Share Issue | Q2 2021
Financial Adviser
Sprint Bioscience
SEK 21m | Directed Share Issue | Q2 2021
Financial Adviser
CombiGene
SEK 75m | Rights Issue | Q1 2021
Financial Adviser
SiB Solutions
SEK 23m | Private Placement | Q4 2020
Financial Adviser
Xintela
SEK 37m | Warrants | Q4 2020
Financial Adviser
NextCell Pharma
SEK 150m | Rights Issue | Q4 2020
Financial Adviser
Scandion Oncology
SEK 236m | Rights Issue | Q4 2020
Financial Adviser
Moberg Pharma
SEK 150m | Rights Issue | Q4 2020
Financial Adviser
SciBase
SEK 32m | Warrants | Q4 2020
Financial Adviser
A3P Biomedical
SEK 110m | Private Placement | Q3 2020
Financial Adviser
Fundler
SEK 17m | Private Placement | Q2 2020
Financial Adviser
Xintela
SEK 40,5m | Rights Issue | Q2 2020
Financial Adviser
LIDDS
SEK 59,3m | Directed & Rights Issue | Q2 2020
Sole Bookrunner
Immunovia
SEK 400m | Directed Share Issue | Q2 2020
Joint Bookrunner
Xbrane Biopharma
SEK 146m | Directed Share Issue | Q2 2020
Global Coordinator and Sole Bookrunner
NextCell Pharma
SEK 25m | Rights Issue | Q2 2020
Financial Adviser
SciBase Holding
SEK 25m | Rights Issue | Q2 2020
Financial Adviser
Plastics Unbound
SEK 21,7m | Private Placement | Q4 2019
Financial Adviser
SenzaGen
SEK 106m | Directed & Rights Issue | Q4 2019
Sole Bookrunner
Nanoform
SEK 106m | Private Placement | Q2 2019
Financial Adviser
Empros Pharma
SEK 40m | Private Placement | Q2 2019
Financial Adviser
Xbrane Biopharma
SEK 238m | Directed & Rights Issue | Q2 2019
Sole Bookrunner
Bio-Works
SEK 70m | Directed & Rights Issue | Q2 2019
Sole Bookrunner
Xbrane Biopharma
SEK 59m | Rights Issue | Q1 2019
Financial Adviser
Ascelia Pharma
SEK 200m | IPO | Q1 2019
Sole Global Coordinator and Bookrunner
AlzeCure
SEK 200m | IPO | Q4 2018
Sole Global Coordinator and Bookrunner
Nanoform
SEK 71m | Private Placement | Q2 2018
Financial Adviser
AlzeCure
SEK 40m | Private Placement | Q2 2018
Financial Adviser
Immunovia
SEK 324m | Direct share issue | Q2 2018
Sole Bookrunner
Plastics Unbound
SEK 50m | Private Placement | Q2 2018
Financial Adviser
Ascelia Pharma
SEK 60m | Private Placement | Q1 2018
Financial Adviser
Bio-Works
SEK 80m | IPO | Q4 2017
Sole Bookrunner
IRRAS
SEK 334m | IPO | Q4 2017
Financial Advisor
SenzaGen
SEK 90,1m | IPO | Q3 2017
Sole Bookrunner
TerraNet
SEK 100m | IPO | Q2 2017
Sole Bookrunner
Bio-Works
SEK 30m | Private Placement | Q2 2017
Financial Adviser
AlzeCure
SEK 70m | Private Placement | Q2 2017
Financial Adviser
Biovica
SEK 60m | IPO | Q1 2017
Sole Bookrunner
Acarix
SEK 140,4m | IPO | Q4 2016
Sole Bookrunner
Immunovia
SEK 189,9m + 28,7m | Q3 2016
Private Placement & Rights Issue
Sole Bookrunner
Xbrane Biopharma
SEK 100m | IPO Q4 | 2015
Sole Bookrunner
Vikingaliv
SEK 113,6m | Private Placement | Q2 2015
Financial Adviser